MAIA Biotechnology Files 8-K: Material Agreement & Equity Sales

TL;DR

MAIA Bio inked a big deal and sold some stock, filing an 8-K on 12/9.

AI Summary

MAIA Biotechnology, Inc. announced on December 9, 2024, that it entered into a material definitive agreement. The company also reported on unregistered sales of equity securities and other events. The filing includes financial statements and exhibits.

Why It Matters

This 8-K filing indicates significant corporate activity for MAIA Biotechnology, including a new material agreement and equity transactions, which could impact its financial standing and future operations.

Risk Assessment

Risk Level: medium — The filing details a material definitive agreement and unregistered sales of equity, which can introduce financial and operational risks.

Key Players & Entities

• MAIA Biotechnology, Inc. (company) — Registrant
• December 9, 2024 (date) — Date of earliest event reported
• 444 West Lake Street, Suite 1700 (address) — Principal executive offices
• Chicago, IL 60606 (address) — Principal executive offices

FAQ

Key Financial Figures

• $0.0001 — f the Company's common stock, par value $0.0001 per share (" Common Stock "), and (ii)
• $1 — f Common Stock, at a price per share of $1.872, for an aggregate purchase price of
• $802,987 — gregate purchase price of approximately $802,987. The Warrants are exercisable at a pri
• $2 — are exercisable at a price per Share of $2.08, which price represents the greater
• $1.872 — e " Warrants ") at a price per share of $1.872 for an aggregate purchase price of appr
• $146,798 — gregate purchase price of approximately $146,798 The Director Warrants are exercisable a
• $2.08 — Warrants are exercisable at a price of $2.08 per share, which price represents the g
• $46,800 — gregate purchase price of approximately $46,800 and Company director Ramiro Guerrero su
• $100,000 — gregate purchase price of approximately $100,000. In addition, Sylvia Guerrero, the si
• $10,000 — gregate purchase price of approximately $10,000. The Shares and the Warrants (and the
• $950,000 m — ferings is expected to be approximately $950,000 million, prior to deducting offering expe

Filing Documents

• d899097d8k.htm (8-K) — 34KB
• d899097dex41.htm (EX-4.1) — 72KB
• d899097dex42.htm (EX-4.2) — 64KB
• d899097dex101.htm (EX-10.1) — 366KB
• d899097dex991.htm (EX-99.1) — 8KB
• 0001193125-24-273921.txt ( ) — 815KB
• maia-20241209.xsd (EX-101.SCH) — 3KB
• maia-20241209_lab.xml (EX-101.LAB) — 18KB
• maia-20241209_pre.xml (EX-101.PRE) — 11KB
• d899097d8k_htm.xml (XML) — 4KB

Financial Statements and Exhibits

Financial Statements and Exhibits (d) Exhibits. Exhibit No. Description 4.1 Form of Investor Warrant 4.2 Form of Director Warrant 10.1* Form of Securities Purchase Agreement 99.1 Press Release dated December 9, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). * The schedules (and similar attachments) to this exhibit have been omitted from this filing pursuant to Item 601(b)(10) of Regulation S-K. The Company agrees to furnish a supplemental copy of any omitted schedule (or similar attachment) to the Securities and Exchange Commission upon request. 3

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: December 10, 2024 MAIA BIOTECHNOLOGY, INC. By: /s/ Vlad Vitoc Name: Vlad Vitoc Title: Chief Executive Officer 4

View Full Filing

View this 8-K filing on SEC EDGAR